Defender Capital LLC. Raises Stock Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Defender Capital LLC. boosted its stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 5.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,310,873 shares of the company's stock after acquiring an additional 347,525 shares during the quarter. Lineage Cell Therapeutics comprises about 1.1% of Defender Capital LLC.'s investment portfolio, making the stock its 13th biggest position. Defender Capital LLC. owned 2.86% of Lineage Cell Therapeutics worth $2,840,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of LCTX. Two Sigma Advisers LP boosted its position in shares of Lineage Cell Therapeutics by 312.2% during the fourth quarter. Two Sigma Advisers LP now owns 86,964 shares of the company's stock valued at $44,000 after buying an additional 65,864 shares during the period. Two Sigma Investments LP bought a new stake in shares of Lineage Cell Therapeutics during the 4th quarter worth approximately $152,000. Barclays PLC lifted its stake in shares of Lineage Cell Therapeutics by 10.8% during the 4th quarter. Barclays PLC now owns 234,069 shares of the company's stock worth $118,000 after acquiring an additional 22,769 shares during the last quarter. Comerica Bank boosted its holdings in Lineage Cell Therapeutics by 220.0% during the 4th quarter. Comerica Bank now owns 800,000 shares of the company's stock valued at $402,000 after acquiring an additional 550,000 shares during the period. Finally, Renaissance Technologies LLC grew its position in Lineage Cell Therapeutics by 1,058.3% in the 4th quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company's stock valued at $1,147,000 after acquiring an additional 2,085,972 shares during the last quarter. 62.47% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

LCTX has been the topic of a number of recent research reports. D. Boral Capital reissued a "buy" rating and set a $2.00 price target on shares of Lineage Cell Therapeutics in a research report on Monday, June 23rd. B. Riley lowered their price objective on shares of Lineage Cell Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a research note on Friday, March 14th. Finally, HC Wainwright reiterated a "buy" rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Monday, June 23rd. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Lineage Cell Therapeutics presently has an average rating of "Buy" and an average target price of $4.20.

Lineage Cell Therapeutics Stock Down 1.0%

Shares of NYSEAMERICAN LCTX traded down $0.01 during mid-day trading on Friday, reaching $1.01. 912,561 shares of the company were exchanged, compared to its average volume of 1,594,110. Lineage Cell Therapeutics, Inc. has a 1 year low of $0.37 and a 1 year high of $1.15. The firm has a 50-day moving average of $0.68 and a 200 day moving average of $0.62. The stock has a market cap of $230.64 million, a price-to-earnings ratio of -12.63 and a beta of 1.60.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.